7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins. Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding. In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus. The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen. The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture. Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein. The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen. Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss. Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

          Background The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur. Aim We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available. Methods Here we present a validated diagnostic workflow for 2019-nCoV, its design relying on close genetic relatedness of 2019-nCoV with SARS coronavirus, making use of synthetic nucleic acid technology. Results The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses. Control material is made available through European Virus Archive – Global (EVAg), a European Union infrastructure project. Conclusion The present study demonstrates the enormous response capacity achieved through coordination of academic and public laboratories in national and European research networks.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

            A software tool, cryoSPARC, addresses the speed bottleneck in cryo-EM image processing, enabling automated macromolecular structure determination in hours on a desktop computer without requiring a starting model.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              UCSF ChimeraX : Structure visualization for researchers, educators, and developers

              UCSF ChimeraX is the next-generation interactive visualization program from the Resource for Biocomputing, Visualization, and Informatics (RBVI), following UCSF Chimera. ChimeraX brings (a) significant performance and graphics enhancements; (b) new implementations of Chimera's most highly used tools, many with further improvements; (c) several entirely new analysis features; (d) support for new areas such as virtual reality, light-sheet microscopy, and medical imaging data; (e) major ease-of-use advances, including toolbars with icons to perform actions with a single click, basic "undo" capabilities, and more logical and consistent commands; and (f) an app store for researchers to contribute new tools. ChimeraX includes full user documentation and is free for noncommercial use, with downloads available for Windows, Linux, and macOS from https://www.rbvi.ucsf.edu/chimerax.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Plant Sci
                Front Plant Sci
                Front. Plant Sci.
                Frontiers in Plant Science
                Frontiers Media S.A.
                1664-462X
                07 March 2023
                2023
                07 March 2023
                : 14
                : 1146234
                Affiliations
                [1] 1 Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town , Cape Town, South Africa
                [2] 2 Wellcome Trust Centre for Infectious Disease Research in Africa, University of Cape Town , Cape Town, South Africa
                [3] 3 Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town , Cape Town, South Africa
                [4] 4 Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town , Cape Town, South Africa
                [5] 5 International Centre for Genetic Engineering and Biotechnology, Observatory, Cape Town , Cape Town, South Africa
                [6] 6 School of Biological Sciences and Institute of Life Sciences, University of Southampton , Southampton, United Kingdom
                [7] 7 Pathcare VetLab , Cape Town, South Africa
                [8] 8 Electron Microscope Unit, University of Cape Town , Cape Town, South Africa
                [9] 9 Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University Tygerberg Campus , Cape Town, South Africa
                [10] 10 Department of Medical Biosciences, University of the Western Cape , Cape Town, South Africa
                [11] 11 Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences , Vienna, Austria
                Author notes

                Edited by: Qiang Chen, Arizona State University, United States

                Reviewed by: Michele Bellucci, National Research Council (CNR), Italy; Hugh S. Mason, Arizona State University, United States

                *Correspondence: Ros Chapman, ros.chapman@ 123456uct.ac.za ; Emmanuel Margolin, emmanuel.margolin@ 123456gmail.com

                This article was submitted to Plant Biotechnology, a section of the journal Frontiers in Plant Science

                Article
                10.3389/fpls.2023.1146234
                10028082
                36959936
                97eabd75-8f68-48ca-b6f3-ecbcec1ae002
                Copyright © 2023 Margolin, Schäfer, Allen, Gers, Woodward, Sutherland, Blumenthal, Meyers, Shaw, Preiser, Strasser, Crispin, Williamson, Rybicki and Chapman

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 17 January 2023
                : 17 February 2023
                Page count
                Figures: 5, Tables: 0, Equations: 0, References: 70, Pages: 14, Words: 7308
                Funding
                Funding for the recombinant protein production described in this manuscript was supported in part by core funding provided by the Wellcome Trust [203135/Z/16/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. EM was supported by scholarship funding from CIDRI Africa. The immunogenicity and challenge work in this manuscript was funded by the UCT Innovation Builder Fund (Project #IB20-14). Further supplementary funding was provided by the South African Research Chairs Initiative of the Department of Science and Technology and the National Research Foundation (grant number: 64815). GS is supported by EDCTP2 programme (Training and Mobility Action TMA2018SF-2446) and receives funding from the NRF, the MRC and the PRF. SARS-CoV-2 isolation and propagation was partially supported by the South African Medical Research Council with funds received from the Department of Science and Innovation (MS and WP), and by the Poliomyelitis Research Foundation (WP, grant 21/81). ADS was supported by a bursary from the Poliomyelitis Research Foundation (grant 21/45). RS was supported by the Austrian Science Fund (FWF) Project P31920-B32. MB holds a ACSR Young Investigator Pilot Award and has received funding from the NRF and the Oppenheimer Memorial Trust. This work was also supported by the International AIDS Vaccine Initiative (IAVI) through grant INV- 008352/OPP1153692 funded by the Bill and Melinda Gates Foundation (MC).
                Categories
                Plant Science
                Original Research

                Plant science & Botany
                sars-cov-2,vaccine,glycoprotein,glycosylation,immunogenicity,challenge
                Plant science & Botany
                sars-cov-2, vaccine, glycoprotein, glycosylation, immunogenicity, challenge

                Comments

                Comment on this article